Moderna has signed a revised supply agreement with the UK government to supply up to 60 million doses of its Covid-19 vaccine. The company plans to deliver up to 29 million doses next year and up to 31 million doses in 2023. The agreement includes an option that will enable the UK government to increase or decrease purchase volumes by up to 20%. The deal may include authorised booster vaccine candidates.
Cofepris, the health regulator in Mexico, has authorised emergency use of Eli Lilly and Co‘s Covid-19 antibody treatment amid increasing concerns over the new emerging variant Omicron. The treatment, an injectable combination of bamlanivimab and etesevimab, was approved for use on patients above 12 years of age with mild to moderate coronavirus. Patients must weigh at least 40kg to receive the treatment. Previously, Lilly’s Covid-19 antibody treatment was approved by the US Food and Drug Administration.
Belgium is planning to purchase Merck & Co’s Covid-19 antiviral oral pill molnupiravir. Belgian health minister Franck Vandenbroucke was quoted by Reuters as saying that the country plans to buy around 10,000 doses of molnupiravir. He added that Belgium is in favour of a joint procurement by the European nations. Merck developed the Covid-19 antiviral pill jointly with Ridgeback Biotherapeutics. Recently, a US FDA panel recommended Merck’s antiviral pill for Covid-19 patients at high risk of developing severe disease.